Marienhospital Bottrop gGmbH
- Address
- lock Available on a paid plan
Neoplasms – Breast Cancer Research
The department at Marienhospital Bottrop gGmbH conducts extensive studies on Breast Cancer, exploring innovative treatments across multiple sub‑types such as HER2‑positive, HR+/HER2‑negative and triple‑negative disease. Trials aim to improve survival, reduce recurrence, and assess the safety of novel drug combinations.
- Targeted antibody‑drug conjugates
- CDK4/6 inhibitor‑based regimens
- Immunotherapy combined with chemotherapy
- Biomarker‑driven precision medicine
- Adjuvant endocrine therapy optimization
With 11 investigators leading 29 active trials, the site provides patients access to cutting‑edge therapies while generating data that could shape future standards of care for breast cancer.
Hormonal Diseases – Endocrine‑Driven Breast Cancer
Research focuses on hormone‑responsive tumors, evaluating new selective estrogen receptor degraders (SERDs) and combinations with CDK4/6 inhibitors to overcome resistance. Studies also measure the impact of treatments on menopausal symptoms and overall quality of life.
- Oral SERD development and comparison
- Combination strategies with CDK4/6 inhibitors
- Genomic profiling for therapy selection
- Management of vasomotor symptoms
- Health‑related quality‑of‑life assessments
These investigations support personalized endocrine therapy, aiming to extend disease‑free survival for patients with hormone‑receptor positive breast cancer.
Nervous System Diseases – Parkinson’s Disease
The clinic participates in trials addressing motor complications in Parkinson Disease. A key focus is the use of intestinal levodopa/entacapone (LECIG) therapy to stabilize dopaminergic signaling and reduce neuropsychiatric side effects.
- LECIG formulation efficacy evaluation
- Assessment of hyperdopaminergic symptom control
- Patient education and adherence programs
- Digital monitoring of motor fluctuations
- Long‑term safety and tolerability studies
By integrating patient‑centered approaches, the site contributes to improving daily functioning and quality of life for individuals living with Parkinson’s disease.
Environment and Public Health – Patient‑Centric Outcomes
Beyond disease‑specific trials, the department evaluates how tailored interventions affect broader health outcomes. Research includes education‑driven adherence strategies and the measurement of health‑related quality of life in cancer patients.
- Coaching programs to enhance treatment persistence
- Quality‑of‑life monitoring using patient‑reported outcomes
- Real‑world data collection for public health insights
- Community outreach for early detection awareness
- Integration of digital health tools in routine care
These projects aim to translate clinical findings into tangible benefits for the wider population, reinforcing the hospital’s commitment to public health excellence.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 4 therapeutic areas and 15 of 47 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 46 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Marienhospital Bottrop gGmbH
lock Showing 1 of 31 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease | Gilead Sciences Inc. | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 47 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Letrozole | 7 | Unknown | 2019-05-22 | 2025-07-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.